NEW YORK — The generic drug user fee program may have hit a speed bump due to budget problems in Congress, according to published reports.
Bloomberg reported that implementation of the law may be delayed because Congress must first pass legislation authorizing the Food and Drug Administration to collect money from generic drug companies, but the problem is that members of Congress will leave Washington this week, not to return until after the Nov. 6 elections.
